TP53 and cancer: Recognized as one of the deadliest cancers, PDAC often carries TP53 mutations, which, through their gain-of-function effects, are known to impact the secretion of signaling molecules, driving processes such as tumorigenesis, immune evasion, drug resistance, and metastasis.